항암치료 병용요법에 있어서 Exosome 기반 약물전달시스템의 적용

키워드

참고문헌 (40)

1. Thakur A, "Exosomes: Small vesicles with big roles in cancer, vaccine development, and therapeutics", Bioact Mater, 10, pp.281~294 (2022)
2. Bayat Mokhtari R, "Combination therapy in combating cancer", Oncotarget, 8(23), pp.38022~38043 (2017)
3. Ismail M, "Prevalence and significance of potential drugdrug interactions among cancer patients receiving chemotherapy", BMC Cancer, 20(1), pp.335~ (2020)
4. Tolcher AW, "Improving combination cancer therapy: the Combi-Plex(®) development platform", Future Oncol, 14(13), pp.1317~1332 (2018)
5. Zhang Y, "Exosomes:biogenesis, biologic function and clinical potential", Cell Biosci, 9(1), pp.19~ (2019)
6. "Lexi-Drugs Multinational :Doxil" (2023)[URL]
7. "Lexi-Drugs Multinational :Myocet" (2023)[URL]
8. "Lexi-Drugs Multinational :DaunoXome" (2023)[URL]
9. "Lexi-Drugs Multinational :Depocyt" (2023)[URL]
10. "Lexi-Drugs Multinational :Mepact" (2023)[URL]
11. Kager L, "Review of mifamurtide in the treatment of patients with osteosarcoma", Ther Clin Risk Manag, 6, pp.279~286 (2010)
12. "Lexi-Drugs Multinational :Marquibo" (2023)[URL]
13. Valadi H, "Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells", Nat Cell Biol, 9(6), pp.654~659 (2007)
14. Thery C, "Exosomes: composition, biogenesis and function", Nat Rev Immunol, 2(8), pp.569~579 (2002)
15. Dai J, "Exosomes:key players in cancer and potential therapeutic strategy", Signal Transduct Target Ther, 5(1), pp.145~ (2020)
16. Maia J, "Exosome-Based Cell-Cell Communication in the Tumor Microenvironment", Front Cell Dev Biol, 6, pp.18~ (2018)
17. Xu Z, "Exosome -based immunotherapy: a promising approach for cancer treatment", Mol Cancer, 19(1), pp.160~ (2020)
18. Rao Q, "Tumor-derived exosomes elicit tumor suppression in murine hepatocellular carcinoma models and humans in vitro", Hepatology, 64(2), pp.456~472 (2016)
19. Record M, "Intercellular communication by exosomes in placenta: a possible role in cell fusion?", Placenta, 35(5), pp.297~302 (2014)
20. Minciacchi VR, "Extracellular vesicles in cancer:exosomes, microvesicles and the emerging role of large oncosomes", Semin Cell Dev Biol, 40, pp.41~51 (2015)
21. Shen M, "Progress in exosome associated tumor markers and their detection methods", Mol Biomed, 1(1), pp.3~ (2020)
22. Banks WA, "Transport of Extracellular Vesicles across the Blood-Brain Barrier: Brain Pharmacokinetics and Effects of Inflammation", Int J Mol Sci, 21(12), pp.4407~ (2020)
23. Matsumoto Y, "Quantification of plasma exosome is a potential prognostic marker for esophageal squamous cell carcinoma", Oncol Rep, 36(5), pp.2535~2543 (2016)
24. Kar R, "Exosome-Based Smart Drug Delivery Tool for Cancer Theranostics", ACS Biomater Sci Eng, 9(2), pp.577~594 (2023)
25. "Announcement contents such as anti-cancer chemotherapy" (2023)[URL]
26. Fan Y, "Responsive Dual-Targeting Exosome as a Drug Carrier for Combination Cancer Immunotherapy", Research(Wash D C), 2021, pp.9862876~ (2021)
27. Frampton JE, "Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma", Drugs, 80(10), pp.1007~1018 (2020)
28. Collea RP, "Pegylated liposomal doxorubicin plus carboplatin in patients with metastatic breast cancer: a phase II study", Ann Oncol, 23(10), pp.2599~2605 (2012)
29. Nguyen, J., "Carboplatin and Liposomal Doxorubicin for Ovarian Cancer", Hosp Pharm, 51(6), pp.442~449 (2016)
30. Gabizon AA, "New insights and evolving role of pegylated liposomal doxorubicin in cancer therapy", Drug Resist Updat, 29, pp.90~106 (2016)
31. Yong T, "Tumor exosome-based nanoparticles are efficient drug carriers for chemotherapy", Nat Commun, 10(1), pp.3838~ (2019)
32. Kim MS, "Engineering macrophage-derived exosomes for targeted paclitaxel delivery to pulmonary metastases: in vitro and in vivo evaluations", Nanomedicine, 14(1), pp.195~204 (2018)
33. Pascucci L, "Paclitaxel is incorporated by mesenchymal stromal cells and released in exosomes that inhibit in vitro tumor growth: a new approach for drug delivery", J Control Release, 192, pp.262~270 (2014)
34. Chen YS, "Exosomes in clinical trial and their production in compliance with good manufacturing practice", Tzu Chi Med J, 32(2), pp.113~120 (2020)
35. Kamerkar S, "Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer", Nature, 546(7659), pp.498~503 (2017)
36. Andrews DW, "Results of a pilot study involving the use of an antisense oligodeoxynucleotide directed against the insulin-like growth factor type I receptor in malignant astrocytomas", J Clin Oncol, 19(8), pp.2189~2200 (2001)
37. Li I, "Exosomes in the tumor microenvironment as mediators of cancer therapy resistance", Mol Cancer, 18(1), pp.32~ (2019)
38. Kim SM, "Cancer-derived exosomes as a delivery platform of CRISPR", Cas9 confer cancer cell tropism-dependent targeting, 2017, pp.266, 8~16
39. Romagnoli GG, "Dendritic Cell-Derived Exosomes may be a Tool for Cancer Immunotherapy by Converting Tumor Cells into Immunogenic Targets", Front Immunol, 5, pp.692~ (2014)
40. Aspe JR, "Enhancement of Gemcitabine sensitivity in pancreatic adenocarcinoma by novel exosome-mediated delivery of the Survivin-T34A mutant", J Extracell Vesicles, 3 (2014)

관련 논문AI추천